Willow Biosciences Inc. (OTCQB: CANSF) (TSX:WLLW) released its financial and operating results for the three months ended March 31, 2023, revealing revenue of CA$274,000  ($203,000) compared to no revenue in Q1 2022. The company is in the development stage and expects to operate at a loss and use cash in operating activities as it conducts research and development on its biosynthesis pathways.

"The first quarter of this year marked significant progress against our stated goals to foster diversified commercial growth within our portfolio, and create opportunities for near-term revenue generation for the business all while experiencing reduced cash burn", stated Chris Savile, Willow's president and CEO. "We are on a solid trajectory in successfully executing on projects underway while pursuing new agreements, and our legacy yeast strain engineering capabilities along with …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.